ACADIA Pharmaceuticals Inc
$ 21.76
-1.18%
15 Apr - close price
- Market Cap 3,754,291,000 USD
- Current Price $ 21.76
- High / Low $ 22.32 / 21.72
- Stock P/E 9.57
- Book Value 7.21
- EPS 2.30
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.40 %
- 52 Week High 28.35
- 52 Week Low 14.08
About
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
Analyst Target Price
$31.80
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-02 | 2025-11-05 | 2025-08-07 | 2025-05-06 | 2025-02-25 | 2024-11-06 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-02 | 2023-08-02 | 2023-05-08 |
| Reported EPS | 0.1375 | 0.42 | 0.16 | 0.11 | 0.86 | 0.2 | 0.2 | 0.1 | 0.28 | -0.4 | 0.01 | -0.27 |
| Estimated EPS | 0.1389 | 0.14 | 0.14 | 0.05 | 0.219 | 0.14 | 0.18 | 0.05 | 0.3 | -0.43 | -0.08 | -0.21 |
| Surprise | -0.0014 | 0.28 | 0.02 | 0.06 | 0.641 | 0.06 | 0.02 | 0.05 | -0.02 | 0.03 | 0.09 | -0.06 |
| Surprise Percentage | -1.0079% | 200% | 14.2857% | 120% | 292.6941% | 42.8571% | 11.1111% | 100% | -6.6667% | 6.9767% | 112.5% | -28.5714% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACAD
2026-04-15 22:09:19
Acadia Pharmaceuticals Inc. announced it will report its first-quarter 2026 financial results on Wednesday, May 6, 2026, after U.S. financial markets close. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the results. This report is expected to provide important insights into the company's performance and progress in its neurological drug pipeline.
2026-04-15 20:09:19
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced it will report its first-quarter 2026 financial results on Wednesday, May 6, 2026, after the U.S. financial markets close. The company's management team will also host a conference call and webcast on the same day at 4:30 p.m. Eastern Time, accessible via Acadia’s website. This announcement aligns with Acadia's commitment to transparency regarding its financial performance and ongoing developments in neurological and rare disease treatments.
2026-04-15 16:09:19
ACADIA Pharmaceuticals has launched DAYBUE STIX, a new oral solution formulation for Rett syndrome, which offers greater flexibility for caregivers and reinforces the drug's role as a standard of care in the US. While this enhances DAYBUE's growth in the domestic market, the recent negative opinion from the EMA for trofinetide indicates potential challenges for international expansion. The article suggests investors should consider the company's reliance on its two main products, NUPLAZID and DAYBUE, and how the STIX formulation could influence future revenue and earnings projections.
2026-04-14 13:39:17
ACADIA Pharmaceuticals, known for Nuplazid and Daybue, faces a critical test in sustaining growth via its expanding CNS product pipeline amid fierce biotech competition. The company's focus on unmet needs in neurology and rare diseases provides market relevance, but investors need to assess if commercial progress translates into broader upside. Analysts generally view ACADIA positively, but highlight execution risks and the need for successful pipeline diversification beyond its two currently approved drugs.
2026-04-14 04:39:17
Acadia Pharmaceuticals has launched a powder formulation of its drug Daybue (trofinetide) for Rett syndrome in the United States. This new formulation aims to provide an easier administration option for patients who may struggle with the liquid version, enhancing adherence and overall patient care. The powder can be mixed with food or liquids, offering greater flexibility.
2026-04-12 05:39:24
ACADIA Pharmaceuticals announced that Allergan Inc. has advanced a novel small molecule for glaucoma into preclinical development, stemming from their collaborative research. ACADIA is eligible for milestone payments and future royalties. This collaboration highlights both companies' strengths in developing treatments for neurological and ophthalmic conditions.
